Although the causes of polycystic ovary syndrome (PCOS) are unclear, researchers know this condition leads to endometrial ...

Neurodegenerative pathologies, once primarily associated with protein alterations, should be revisited in the context of ...

Biomedical research seems like it should be the ultimate bipartisan issue. But under the Trump administration, unless and ...

Amygdala Neurosciences Inc. has selected ANS-858 as its lead clinical candidate for substance use disorders, that includes ...

President Donald Trump’s executive order on global tariffs have pushed downward the stocks of biopharma and med-tech ...

The U.S. FDA cleared Artrya Ltd.’s Salix Coronary Anatomy software that analyzes coronary computed tomography angiogram scans ...

Spark Therapeutics Inc. has presented a proprietary adeno-associated viral (AAV) vector expressing an artificial miRNA targeting human α-synuclein (α-Syn) mRNA. Accumulation of misfolded and insoluble ...

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is an attractive therapeutic target due to its involvement in cancer and neurodegenerative diseases. Researchers from the ...

Resvita Bio Inc.’s RVB-003 has been awarded orphan drug designation by the FDA for the skin disorder Netherton syndrome. RVB-003 was previously granted rare pediatric disease designation.

Sangamo Therapeutics Inc. has entered into a license agreement with Eli Lilly and Co., allowing Lilly to use Sangamo’s novel proprietary neurotropic AAV capsid, STAC-BBB, to deliver intravenously ...

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award Arrepath Inc. $3.7 million to execute a lead optimization workplan for its first-in-class antibiotic targeting ...

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing Manage cookie preferences ...